Modulation of Autophagy: A Clinical Study of Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC) Patients (CTMS# 14-2015)

Trial Profile

Modulation of Autophagy: A Clinical Study of Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC) Patients (CTMS# 14-2015)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2016

At a glance

  • Drugs Vorinostat (Primary) ; Hydroxychloroquine; Regorafenib
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Apr 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
    • 19 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top